Breakthrough gene therapy restores hearing in children with inherited deafness
HQ Team August15, 2024: A clinical trial has successfully restored hearing in five children suffering from inherited deafness by administering gene therapy to.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team August15, 2024: A clinical trial has successfully restored hearing in five children suffering from inherited deafness by administering gene therapy to.
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.
Sixty percent of the patients treated with Pfizer’s Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.
HQ Team April 9, 2024: Synchron, a US-based brain implant company, plans to recruit motor-impaired patients for its clinical trial in competition with.
HQ Team June 7, 2023: Ropinirole, a drug already approved for the treatment of Parkinson’s disease, has shown potential as a treatment for.
Merck's COVID-19 pill does not stop the risk of prevention of the virus spreading to others in a household, the company stated.
Novavax, a US biotechnology company, announced it would deliver 1.5 million doses of its COVID-19 adjuvanted vaccine to the government.
The USFDA has put on hold Blueprint Medicines Corporation's clinical trial of BLU-222 due to visual adverse events seen in some patients, according.
Johnson & Johnson stopped the phase III trial of its global HIV vaccine trial after it found that the regimen was ineffective in.
Merck's Covid-19 pill no help in reducing hospitalization or death, Astrazenaca's nasal spray too fails trial